We read with great interest the prospective cohort study by Dos Santos et al. published in the European Journal of Internal Medicine [1]. This study focused on VTE risk assessment in patients with HaH and proposed a TROMBODOM model for this purpose. The authors reported that, despite a higher proportion of high-risk scores in the HaH group, the 90-day VTE incidence was lower in this group than in the CH group (1.2%vs. 3.5%), leading them to suggest that traditional risk models may overestimate the thrombotic risk in HaH patients.
